Evidence map›Paper›PMID 32842691›Full record

ArticlePathogens (Basel, Switzerland)2020

In Vitro Evaluation of Farnesyltransferase Inhibitor and its Effect in Combination with 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor against

Hye Jee Hahn, Anjan Debnath

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Approaches for TargetingPathogens (Basel, Switzerland) · 2024
    Review
  5. Opportunistic free-living amoebal pathogens.Pathogens and global health · 2022
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hye Jee HahnCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Anjan DebnathCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-9294-3927
University of California San Diego · US

Funding

UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
HMG-CoA Reductase Inhibitors as New Drug Leads for Naegleria InfectionR21AI146460 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEBNATH, ANJAN · 2020 to 2021
$433k
NCATS NIH HHS KL2 TR001444NIAID NIH HHS R21 AI146460NIH HHS 1KL2TR001444, 1R21AI146460
6 · The paper itself

Abstract

Free-living amoeba

Indexed as

3-hydroxy-3-methyl-glutaryl-CoA reductasefarnesyltransferasefree-living amoebalonafarnibNaegleria fowleripitavastatinprimary amoebic meningoencephalitis

Identifiers

PMID32842691
PMCPMC7560193
OpenAlexW3080408192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.